GlassScriptPhysician profile
Ranadev Mukherjee
NPI 1861593790
$845.62
in general payments reported to CMS, 2019-2025
14 companies · $179 in 2025
The $179 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35.55 · 2020: $19.79 · 2021: $179 · 2022: $96.51 · 2023: $158 · 2024: $178 · 2025: $179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $514.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $208.33 | 2021-2025 | |
| Janssen Biotech, INC. | $114.97 | 2021-2023 | Stelara, Remicade, Simponi Aria |
| Lilly USA, LLC | $106.12 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.88 | 2024-2025 | Gilotrif |
| Ferring Pharmaceuticals INC. | $56.80 | 2022-2024 | Rebyota |
| Novartis Pharmaceuticals Corporation | $55.22 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.72 | 2021-2024 | Iclusig |
| Glaxosmithkline, LLC. | $42.37 | 2024 | Ojjaara |
| Tersera Therapeutics LLC | $36.49 | 2025 | Xermelo |
| Pharmacosmos Therapeutics INC. | $31.88 | 2025 | Monoferric |
| Ironwood Pharmaceuticals, INC | $19.79 | 2020 | |
| Qol Medical, LLC | $18.21 | 2019 | |
| Accord Healthcare, INC. | $17.50 | 2024 | |
| Braintree Laboratories, INC. | $17.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ranadev Mukherjee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.